BNP Paribas Financial Markets
SLN

BNP Paribas Financial Markets’s Silence Therapeutics SLN Stock Holding History

BNP Paribas Financial Markets’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$778K Buy
147,668
+135,641
+1,128% +$747K ﹤0.01% 3311
2025
Q4 		$73.1K Buy
12,027
+11,427
+1,905% +$73.2K ﹤0.01% 4514
2025
Q3 		$3.11K Sell
600
-100
-14% -$555 ﹤0.01% 5135
2025
Q2 		$4.06K Sell
700
-4,088
-85% -$17.5K ﹤0.01% 4978
2025
Q1 		$13.5K Buy
4,788
+3,004
+168% +$14.7K ﹤0.01% 4644
2024
Q4 		$12.3K Buy
+1,784
New +$23K ﹤0.01% 4815

Other funds holding SLN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

BNP Paribas Financial Markets's SLN Position: Q1 2026 in Review

BNP Paribas Financial Markets increased its Silence Therapeutics (SLN) stake by 1,128% in Q1 2026, buying an estimated $747K and bringing the position to 147,668 shares worth $778K. The position accounts for ﹤0.01% of the portfolio, ranked #3311.

BNP Paribas Financial Markets first reported a position in SLN in Q4 2024 and has held it in 6 quarters since. 56 funds tracked by Wall St. Rank hold SLN as of Q1 2026.

  • BNP Paribas Financial Markets held 147,668 shares of Silence Therapeutics worth $778K as of Q1 2026.
  • BNP Paribas Financial Markets bought 135,641 Silence Therapeutics shares in Q1 2026, an estimated $747K.
  • Silence Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #3311 holding.
  • BNP Paribas Financial Markets first reported a position in Silence Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 56 funds tracked by Wall St. Rank held Silence Therapeutics as of Q1 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.